Holen Sie sich die Stockscreener-App
7.9546
0.18%
0.0246
Schlusskurs vom Vortag:
$7.93
Offen:
$7.92
24-Stunden-Volumen:
2.05M
Relative Volume:
0.47
Marktkapitalisierung:
$1.93B
Einnahmen:
$386.15M
Nettoeinkommen (Verlust:
$-56.39M
KGV:
-34.59
EPS:
-0.23
Netto-Cashflow:
$-55.19M
1W Leistung:
+17.69%
1M Leistung:
+36.97%
6M Leistung:
+80.97%
1J Leistung:
+44.18%
1-Tages-Spanne:
$7.85
$8.40
1-Wochen-Bereich:
$6.84
$8.40
52-Wochen-Spanne:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Vergleichen Sie ARDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
7.945 | 1.93B | 386.15M | -56.39M | -55.19M | -0.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-02 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Ardelyx Investors Appeal Dismissal of Medicare Program Lawsuit - Bloomberg Law News
Ardelyx responds to Zydus Lifesciences acquisition reports - CNBC TV18
ZYDUS EYES ARDELYX ACQUISITION DEAL - ICICI Direct
Ardelyx: Assessment Of Acquisition Rumors (NASDAQ:ARDX) - Seeking Alpha
ARDX: Wedbush Raises Price Target to $19, Maintains Outperform R - GuruFocus
Ardelyx (NASDAQ:ARDX) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Ardelyx stock hits 52-week high at 8.06 USD - Investing.com
Wedbush Increases Ardelyx (NASDAQ:ARDX) Price Target to $19.00 - MarketBeat
Lam Research To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Demystifying Ardelyx: Insights From 7 Analyst Reviews - Benzinga
Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength? - Nasdaq
Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry - simplywall.st
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Grapevine: Zydus in talks to acquire US biopharma firm; K Raheja mulls IPO - VCCircle
Wedbush Raises Ardelyx Price Target to $19 Amid Outperform Rating - Intellectia AI
Zydus Lifesciences eyes $2.5 billion US biopharma buyout of Ardelyx: Report - Moneycontrol
Zydus Lifesciences plans to acquire Ardelyx for USD 2.5B - Medical Buyer
Ardelyx (NASDAQ:ARDX) Trading Up 10.2%Here's What Happened - MarketBeat
Ardelyx stock soars on report of potential Zydus Life acquisition - Investing.com
Ardelyx Shares Soar as Analysts Raise Price Targets - StocksToTrade
Ardelyx Stock Surges Amid Upgraded Ratings and Revenue Projections - timothysykes.com
Zydus Lifesciences eyes acquisition of US firm Ardelyx for $2.5 billion | Company Business News - Mint
Ardelyx (ARDX) Surges on Potential Acquisition by Zydus Lifesciences - GuruFocus
Ardelyx: IBSRELA Momentum Drives Opportunity (NASDAQ:ARDX) - Seeking Alpha
Zydus Life may acquire US-firm Ardelyx; may fund deal via QIP - India Infoline
Zydus Life to Acquire Ardelyx, Raise Funds via QIP; Shares Flat - Equitypandit
Zydus Lifesciences in talks to acquire US biopharma firm Ardelyx, may raise ₹5,000 crore via QIP - scanx.trade
Zydus Life may acquire US-firm Ardelyx, may raise funds via QIP to part-fund deal: Exclusive - CNBC TV18
Ardelyx stock rises premarket as Piper sees over 100% upside — says constipation drug 'stole the show' with 2026 guidance - MSN
Lobbying Update: $580,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
Ardelyx says 2025 total product revenue was about $378M - MSN
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Exit Recap: Can Ardelyx Inc continue delivering strong returns2025 Market Sentiment & Real-Time Volume Surge Alerts - baoquankhu1.vn
Ardelyx (ARDX) price target increased by 12.82% to 13.46 - MSN
Insider Buy: Can Ardelyx Inc stock outperform in 2025 bull market2025 Biggest Moves & Consistent Income Trade Ideas - Bộ Nội Vụ
Ardelyx (ARDX) Price Target Increased by 12.82% to 13.46 - Nasdaq
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? - Asianet Newsable
Lobbying Update: $30,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
Ardelyx (NASDAQ:ARDX) Stock Price Down 6.8% on Insider Selling - MarketBeat
Are Medical Stocks Lagging Ardelyx (ARDX) This Year? - Yahoo Finance
Ardelyx Inc: Citigroup raises target price to $14 from $11 - marketscreener.com
Ardelyx chief patient officer Williams sells $348,900 in stock By Investing.com - Investing.com South Africa
Top Ardelyx Executive Executes Significant Stock Sale That Investors Can’t Ignore - TipRanks
Ardelyx chief patient officer Williams sells $348,900 in stock - Investing.com India
Insider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells 50,000 Shares of Stock - MarketBeat
Ardelyx’s Stock Ascends Following Strategic Upgrades and Promising Revenue Projections - StocksToTrade
Why Ardelyx (ARDX) Is Up 20.1% After Lawsuit Dismissal And Patent Extension For Tenapanor - simplywall.st
Ardelyx upgraded at Piper Sandler on Ibsrela (ARDX:NASDAQ) - Seeking Alpha
Assessing Ardelyx (ARDX) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
ARDX Analyst Upgrade: Citigroup Raises Price Target to $14.00 | - GuruFocus
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):